EirGenix Inc. (6589.TW) stock: key figures, P/E, revenue and dividend

Health Care · Taiwan

Price
47.75 TWD
Market cap
14.45 bn TWD
P/E (2025)
–
P/S (2025)
14.38
Dividend yield
0.00 %
Net margin
-75.67 %
Return on equity (ROE)
-9.12 %
Return on assets (ROA)
-6.95 %

EirGenix Inc. financials

Fiscal year20242025
Revenue1.01 bn TWD1.01 bn TWD
Gross profit218.99 m TWD193.83 m TWD
Operating income-865.87 m TWD-843.38 m TWD
EBIT-690.08 m TWD-751.74 m TWD
Net income-698.34 m TWD-760.55 m TWD
Diluted EPS – continuing operations-2.29 TWD-2.51 TWD

Full history since 2021, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About EirGenix Inc.

EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatment of cancer and currently under biologics license application status; EG1206A, a Pertuzumab biosimilar, indicated for the treatment of cancer and currently under Phase I stage; EG13074, indicated for the treatment of cancer and currently under Preclinical stage; TSY0110(EG12043), an antibody-drug conjugate, indicated for the treatment of cancer and currently under Preclinical stage; EG12021, Bevacizumab biosimilar, indicated for the treatment of cancer and currently under Preclinical stage; and EG62054, a biosimilar, currently under Preclinical stage. In addition, the company manufactures and sells covid-19 antigen rapid test; and EG74032, a CRM197 carrier protein. The company was incorporated in 2012 and is headquartered in New Taipei City, Taiwan.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.